次世代抗体医薬品の世界市場レポート2024-2030
英文タイトル: Global Next Generation Antibody Therapeutics Market Insights, Forecast to 2030
販売価格(消費税別)
個人版
マルチユーザー版
企業版
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=150円。
※米ドル表示価格+10%消費税。
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=150円。
※米ドル表示価格+10%消費税。
※ご注文方法:お問い合わせフォームまたはメールにてご連絡ください。
支払方法:「銀行振込」の場合, 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期:原則として、受注後2~4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8~10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。
概要
本報告書は次世代抗体医薬品市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは次世代抗体医薬品の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。
世界の次世代抗体医薬品市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは次世代抗体医薬品のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に次世代抗体医薬品市場を分類しています。本研究に含まれる主な企業は:Roche、Amgen、Pfizer、Takeda、Daiichi Sankyo、Seagen、Astellas、Immunomedics、GSK、Immunocore、ADC Therapeutics
地域別市場区分、地域別分析は以下の通り:
アメリカとカナダ
中国
アジア
ヨーロッパ
中東、アフリカ、ラテンアメリカ
タイプ別市場セグメント:
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
用途別の市場セグメント:
Cancer
Haemophilia
Other Non-Cancer Diseases
本レポートの詳細内容
世界の次世代抗体医薬品市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、次世代抗体医薬品タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の次世代抗体医薬品収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の次世代抗体医薬品市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、次世代抗体医薬品市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。
次世代抗体医薬品のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。
章の概要
第1章:次世代抗体医薬品のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント(製品タイプ、用途など)のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。(2019~2030)
第2章:次世代抗体医薬品の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。(2019~2030)
第3章次世代抗体医薬品企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。(2019~2030)
第4章:各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。(2019~2024)
第5章:次世代抗体医薬品の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。(2019~2030)
第6章:北米(米国、カナダ)のタイプ別、アプリケーション別、国別、各セグメントの収益。(2019~2030)
第7章:ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。(2019~2030)
第8章:中国の種類別、および用途別、各セグメントの収益。(2019~2030)
第9章アジア(中国を除く)の種類別、用途別、地域別、セグメントごとの収益。(2019~2030)
第10章:中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。(2019~2030)
第11章:次世代抗体医薬品の主要企業の概要を提供し、製品の説明と仕様、次世代抗体医薬品の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。(2019~2024)
第12章:アナリストの見解/結論
概要
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities. The global Next Generation Antibody Therapeutics market is projected to grow from US$ 14630 million in 2024 to US$ 43680 million by 2030, at a Compound Annual Growth Rate (CAGR) of 20.0% during the forecast period. The global next-generation antibody therapeutics market is expected to grow significantly over the next decade, driven by the increasing prevalence of cancer, autoimmune diseases, and infectious diseases, along with advancements in biotechnology. Oncology will remain the largest segment, but there will be strong growth in autoimmune diseases, infectious diseases, and neurological conditions. In conclusion, technological advancements, regulatory support, and the increasing use of antibodies in combination therapies will continue to fuel the market's growth, making next-gen antibody therapeutics one of the most promising areas in biopharmaceutical innovation.Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 %. Report Includes This report presents an overview of global market for Next Generation Antibody Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. This report researches the key producers of Next Generation Antibody Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Next Generation Antibody Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries. This report focuses on the Next Generation Antibody Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Next Generation Antibody Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way. This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Next Generation Antibody Therapeutics revenue, projected growth trends, production technology, application and end-user industry. Descriptive company profiles of the major global players, including Roche, Amgen, Pfizer, Takeda, Daiichi Sankyo, Seagen, Astellas, Immunomedics, GSK, Immunocore, etc. Market Segmentation By Company Roche Amgen Pfizer Takeda Daiichi Sankyo Seagen Astellas Immunomedics GSK Immunocore ADC Therapeutics Segment by Type Antibody Drug Conjugate (ADC) Bispecific Antibody (BsAb) Segment by Application Cancer Haemophilia Other Non-Cancer Diseases By Region North America United States Canada Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Europe Germany France U.K. Italy Russia Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of South America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Chapter Outline Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 2: Revenue of Next Generation Antibody Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 3: Detailed analysis of Next Generation Antibody Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment. Chapter 7: Europe by Type, by Application and by country, revenue for each segment. Chapter 8: China by Type, and by Application, revenue for each segment. Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment. Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment. Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Next Generation Antibody Therapeutics revenue, gross margin, and recent development, etc. Chapter 12: Analyst's Viewpoints/Conclusions
総目録
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antibody Drug Conjugate (ADC)
1.2.3 Bispecific Antibody (BsAb)
1.3 Market by Application
1.3.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Haemophilia
1.3.4 Other Non-Cancer Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2019-2030)
2.2 Global Next Generation Antibody Therapeutics Growth Trends by Region
2.2.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Next Generation Antibody Therapeutics Market Dynamics
2.3.1 Next Generation Antibody Therapeutics Industry Trends
2.3.2 Next Generation Antibody Therapeutics Market Drivers
2.3.3 Next Generation Antibody Therapeutics Market Challenges
2.3.4 Next Generation Antibody Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Next Generation Antibody Therapeutics by Players
3.1.1 Global Next Generation Antibody Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Next Generation Antibody Therapeutics, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2023
3.5 Global Key Players of Next Generation Antibody Therapeutics Head office and Area Served
3.6 Global Key Players of Next Generation Antibody Therapeutics, Product and Application
3.7 Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Antibody Therapeutics Breakdown Data by Type
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2025-2030)
5 Next Generation Antibody Therapeutics Breakdown Data by Application
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Next Generation Antibody Therapeutics Market Size (2019-2030)
6.2 North America Next Generation Antibody Therapeutics Market Size by Type
6.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2019-2024)
6.2.2 North America Next Generation Antibody Therapeutics Market Size by Type (2025-2030)
6.2.3 North America Next Generation Antibody Therapeutics Market Share by Type (2019-2030)
6.3 North America Next Generation Antibody Therapeutics Market Size by Application
6.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2019-2024)
6.3.2 North America Next Generation Antibody Therapeutics Market Size by Application (2025-2030)
6.3.3 North America Next Generation Antibody Therapeutics Market Share by Application (2019-2030)
6.4 North America Next Generation Antibody Therapeutics Market Size by Country
6.4.1 North America Next Generation Antibody Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Next Generation Antibody Therapeutics Market Size by Country (2019-2024)
6.4.3 North America Next Generation Antibody Therapeutics Market Share by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Next Generation Antibody Therapeutics Market Size (2019-2030)
7.2 Europe Next Generation Antibody Therapeutics Market Size by Type
7.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2019-2024)
7.2.2 Europe Next Generation Antibody Therapeutics Market Size by Type (2025-2030)
7.2.3 Europe Next Generation Antibody Therapeutics Market Share by Type (2019-2030)
7.3 Europe Next Generation Antibody Therapeutics Market Size by Application
7.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2019-2024)
7.3.2 Europe Next Generation Antibody Therapeutics Market Size by Application (2025-2030)
7.3.3 Europe Next Generation Antibody Therapeutics Market Share by Application (2019-2030)
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country
7.4.1 Europe Next Generation Antibody Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Next Generation Antibody Therapeutics Market Size by Country (2019-2024)
7.4.3 Europe Next Generation Antibody Therapeutics Market Size by Country (2025-2030)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
7.4.9 Nordic Countries
8 China
8.1 China Next Generation Antibody Therapeutics Market Size (2019-2030)
8.2 China Next Generation Antibody Therapeutics Market Size by Type
8.2.1 China Next Generation Antibody Therapeutics Market Size by Type (2019-2024)
8.2.2 China Next Generation Antibody Therapeutics Market Size by Type (2025-2030)
8.2.3 China Next Generation Antibody Therapeutics Market Share by Type (2019-2030)
8.3 China Next Generation Antibody Therapeutics Market Size by Application
8.3.1 China Next Generation Antibody Therapeutics Market Size by Application (2019-2024)
8.3.2 China Next Generation Antibody Therapeutics Market Size by Application (2025-2030)
8.3.3 China Next Generation Antibody Therapeutics Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Next Generation Antibody Therapeutics Market Size (2019-2030)
9.2 Asia Next Generation Antibody Therapeutics Market Size by Type
9.2.1 Asia Next Generation Antibody Therapeutics Market Size by Type (2019-2024)
9.2.2 Asia Next Generation Antibody Therapeutics Market Size by Type (2025-2030)
9.2.3 Asia Next Generation Antibody Therapeutics Market Share by Type (2019-2030)
9.3 Asia Next Generation Antibody Therapeutics Market Size by Application
9.3.1 Asia Next Generation Antibody Therapeutics Market Size by Application (2019-2024)
9.3.2 Asia Next Generation Antibody Therapeutics Market Size by Application (2025-2030)
9.3.3 Asia Next Generation Antibody Therapeutics Market Share by Application (2019-2030)
9.4 Asia Next Generation Antibody Therapeutics Market Size by Region
9.4.1 Asia Next Generation Antibody Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Next Generation Antibody Therapeutics Market Size by Region (2019-2024)
9.4.3 Asia Next Generation Antibody Therapeutics Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Next Generation Antibody Therapeutics Introduction
11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Next Generation Antibody Therapeutics Introduction
11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Next Generation Antibody Therapeutics Introduction
11.3.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Next Generation Antibody Therapeutics Introduction
11.4.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.4.5 Takeda Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Details
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.5.5 Daiichi Sankyo Recent Development
11.6 Seagen
11.6.1 Seagen Company Details
11.6.2 Seagen Business Overview
11.6.3 Seagen Next Generation Antibody Therapeutics Introduction
11.6.4 Seagen Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.6.5 Seagen Recent Development
11.7 Astellas
11.7.1 Astellas Company Details
11.7.2 Astellas Business Overview
11.7.3 Astellas Next Generation Antibody Therapeutics Introduction
11.7.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.7.5 Astellas Recent Development
11.8 Immunomedics
11.8.1 Immunomedics Company Details
11.8.2 Immunomedics Business Overview
11.8.3 Immunomedics Next Generation Antibody Therapeutics Introduction
11.8.4 Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.8.5 Immunomedics Recent Development
11.9 GSK
11.9.1 GSK Company Details
11.9.2 GSK Business Overview
11.9.3 GSK Next Generation Antibody Therapeutics Introduction
11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.9.5 GSK Recent Development
11.10 Immunocore
11.10.1 Immunocore Company Details
11.10.2 Immunocore Business Overview
11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction
11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.10.5 Immunocore Recent Development
11.11 ADC Therapeutics
11.11.1 ADC Therapeutics Company Details
11.11.2 ADC Therapeutics Business Overview
11.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Introduction
11.11.4 ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2019-2024)
11.11.5 ADC Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
表と図のリスト
List of Tables Table 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030 Table 2. Key Players of Antibody Drug Conjugate (ADC) Table 3. Key Players of Bispecific Antibody (BsAb) Table 4. Global Next Generation Antibody Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030 Table 5. Global Next Generation Antibody Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030 Table 6. Global Next Generation Antibody Therapeutics Market Size by Region (2019-2024) & (US$ Million) Table 7. Global Next Generation Antibody Therapeutics Market Share by Region (2019-2024) Table 8. Global Next Generation Antibody Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million) Table 9. Global Next Generation Antibody Therapeutics Market Share by Region (2025-2030) Table 10. Next Generation Antibody Therapeutics Market Trends Table 11. Next Generation Antibody Therapeutics Market Drivers Table 12. Next Generation Antibody Therapeutics Market Challenges Table 13. Next Generation Antibody Therapeutics Market Restraints Table 14. Global Next Generation Antibody Therapeutics Revenue by Players (2019-2024) & (US$ Million) Table 15. Global Next Generation Antibody Therapeutics Market Share by Players (2019-2024) Table 16. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2023) Table 17. Global Next Generation Antibody Therapeutics Industry Ranking 2022 VS 2023 Table 18. Global 5 Largest Players Market Share by Next Generation Antibody Therapeutics Revenue (CR5 and HHI) & (2019-2024) Table 19. Global Key Players of Next Generation Antibody Therapeutics, Headquarters and Area Served Table 20. Global Key Players of Next Generation Antibody Therapeutics, Product and Application Table 21. Global Key Players of Next Generation Antibody Therapeutics, Date of Enter into This Industry Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Next Generation Antibody Therapeutics Market Size by Type (2019-2024) & (US$ Million) Table 24. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2019-2024) Table 25. Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million) Table 26. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2025-2030) Table 27. Global Next Generation Antibody Therapeutics Market Size by Application (2019-2024) & (US$ Million) Table 28. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2019-2024) Table 29. Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million) Table 30. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2025-2030) Table 31. North America Next Generation Antibody Therapeutics Market Size by Type (2019-2024) & (US$ Million) Table 32. North America Next Generation Antibody Therapeutics Market Size by Type (2025-2030) & (US$ Million) Table 33. North America Next Generation Antibody Therapeutics Market Size by Application (2019-2024) & (US$ Million) Table 34. North America Next Generation Antibody Therapeutics Market Size by Application (2025-2030) & (US$ Million) Table 35. North America Next Generation Antibody Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030 Table 36. North America Next Generation Antibody Therapeutics Market Size by Country (2019-2024) & (US$ Million) Table 37. North America Next Generation Antibody Therapeutics Market Size by Country (2025-2030) & (US$ Million) Table 38. Europe Next Generation Antibody Therapeutics Market Size by Type (2019-2024) & (US$ Million) Table 39. Europe Next Generation Antibody Therapeutics Market Size by Type (2025-2030) & (US$ Million) Table 40. Europe Next Generation Antibody Therapeutics Market Size by Application (2019-2024) & (US$ Million) Table 41. Europe Next Generation Antibody Therapeutics Market Size by Application (2025-2030) & (US$ Million) Table 42. Europe Next Generation Antibody Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030 Table 43. Europe Next Generation Antibody Therapeutics Market Size by Country (2019-2024) & (US$ Million) Table 44. Europe Next Generation Antibody Therapeutics Market Size by Country (2025-2030) & (US$ Million) Table 45. China Next Generation Antibody Therapeutics Market Size by Type (2019-2024) & (US$ Million) Table 46. China Next Generation Antibody Therapeutics Market Size by Type (2025-2030) & (US$ Million) Table 47. China Next Generation Antibody Therapeutics Market Size by Application (2019-2024) & (US$ Million) Table 48. China Next Generation Antibody Therapeutics Market Size by Application (2025-2030) & (US$ Million) Table 49. Asia Next Generation Antibody Therapeutics Market Size by Type (2019-2024) & (US$ Million) Table 50. Asia Next Generation Antibody Therapeutics Market Size by Type (2025-2030) & (US$ Million) Table 51. Asia Next Generation Antibody Therapeutics Market Size by Application (2019-2024) & (US$ Million) Table 52. Asia Next Generation Antibody Therapeutics Market Size by Application (2025-2030) & (US$ Million) Table 53. Asia Next Generation Antibody Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030 Table 54. Asia Next Generation Antibody Therapeutics Market Size by Region (2019-2024) & (US$ Million) Table 55. Asia Next Generation Antibody Therapeutics Market Size by Region (2025-2030) & (US$ Million) Table 56. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Type (2019-2024) & (US$ Million) Table 57. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Type (2025-2030) & (US$ Million) Table 58. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Application (2019-2024) & (US$ Million) Table 59. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Application (2025-2030) & (US$ Million) Table 60. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030 Table 61. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Country (2019-2024) & (US$ Million) Table 62. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size by Country (2025-2030) & (US$ Million) Table 63. Roche Company Details Table 64. Roche Business Overview Table 65. Roche Next Generation Antibody Therapeutics Product Table 66. Roche Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 67. Roche Recent Development Table 68. Amgen Company Details Table 69. Amgen Business Overview Table 70. Amgen Next Generation Antibody Therapeutics Product Table 71. Amgen Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 72. Amgen Recent Development Table 73. Pfizer Company Details Table 74. Pfizer Business Overview Table 75. Pfizer Next Generation Antibody Therapeutics Product Table 76. Pfizer Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 77. Pfizer Recent Development Table 78. Takeda Company Details Table 79. Takeda Business Overview Table 80. Takeda Next Generation Antibody Therapeutics Product Table 81. Takeda Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 82. Takeda Recent Development Table 83. Daiichi Sankyo Company Details Table 84. Daiichi Sankyo Business Overview Table 85. Daiichi Sankyo Next Generation Antibody Therapeutics Product Table 86. Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 87. Daiichi Sankyo Recent Development Table 88. Seagen Company Details Table 89. Seagen Business Overview Table 90. Seagen Next Generation Antibody Therapeutics Product Table 91. Seagen Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 92. Seagen Recent Development Table 93. Astellas Company Details Table 94. Astellas Business Overview Table 95. Astellas Next Generation Antibody Therapeutics Product Table 96. Astellas Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 97. Astellas Recent Development Table 98. Immunomedics Company Details Table 99. Immunomedics Business Overview Table 100. Immunomedics Next Generation Antibody Therapeutics Product Table 101. Immunomedics Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 102. Immunomedics Recent Development Table 103. GSK Company Details Table 104. GSK Business Overview Table 105. GSK Next Generation Antibody Therapeutics Product Table 106. GSK Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 107. GSK Recent Development Table 108. Immunocore Company Details Table 109. Immunocore Business Overview Table 110. Immunocore Next Generation Antibody Therapeutics Product Table 111. Immunocore Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 112. Immunocore Recent Development Table 113. ADC Therapeutics Company Details Table 114. ADC Therapeutics Business Overview Table 115. ADC Therapeutics Next Generation Antibody Therapeutics Product Table 116. ADC Therapeutics Revenue in Next Generation Antibody Therapeutics Business (2019-2024) & (US$ Million) Table 117. ADC Therapeutics Recent Development Table 118. Research Programs/Design for This Report Table 119. Key Data Information from Secondary Sources Table 120. Key Data Information from Primary Sources List of Figures Figure 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million) Figure 2. Global Next Generation Antibody Therapeutics Market Share by Type: 2023 VS 2030 Figure 3. Antibody Drug Conjugate (ADC) Features Figure 4. Bispecific Antibody (BsAb) Features Figure 5. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million) Figure 6. Global Next Generation Antibody Therapeutics Market Share by Application: 2023 VS 2030 Figure 7. Cancer Case Studies Figure 8. Haemophilia Case Studies Figure 9. Other Non-Cancer Diseases Case Studies Figure 10. Next Generation Antibody Therapeutics Report Years Considered Figure 11. Global Next Generation Antibody Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030 Figure 12. Global Next Generation Antibody Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030 Figure 13. Global Next Generation Antibody Therapeutics Market Share by Region: 2023 VS 2030 Figure 14. Global Next Generation Antibody Therapeutics Market Share by Players in 2023 Figure 15. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2023) Figure 16. The Top 10 and 5 Players Market Share by Next Generation Antibody Therapeutics Revenue in 2023 Figure 17. North America Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 18. North America Next Generation Antibody Therapeutics Market Share by Type (2019-2030) Figure 19. North America Next Generation Antibody Therapeutics Market Share by Application (2019-2030) Figure 20. North America Next Generation Antibody Therapeutics Market Share by Country (2019-2030) Figure 21. United States Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 22. Canada Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 23. Europe Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 24. Europe Next Generation Antibody Therapeutics Market Share by Type (2019-2030) Figure 25. Europe Next Generation Antibody Therapeutics Market Share by Application (2019-2030) Figure 26. Europe Next Generation Antibody Therapeutics Market Share by Country (2019-2030) Figure 27. Germany Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 28. France Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 29. U.K. Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 30. Italy Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 31. Russia Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 32. Nordic Countries Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 33. China Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 34. China Next Generation Antibody Therapeutics Market Share by Type (2019-2030) Figure 35. China Next Generation Antibody Therapeutics Market Share by Application (2019-2030) Figure 36. Asia Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 37. Asia Next Generation Antibody Therapeutics Market Share by Type (2019-2030) Figure 38. Asia Next Generation Antibody Therapeutics Market Share by Application (2019-2030) Figure 39. Asia Next Generation Antibody Therapeutics Market Share by Region (2019-2030) Figure 40. Japan Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 41. South Korea Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 42. China Taiwan Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 43. Southeast Asia Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 44. India Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 45. Australia Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 46. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 47. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Share by Type (2019-2030) Figure 48. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Share by Application (2019-2030) Figure 49. Middle East, Africa, and Latin America Next Generation Antibody Therapeutics Market Share by Country (2019-2030) Figure 50. Brazil Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 51. Mexico Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 52. Turkey Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 53. Saudi Arabia Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 54. Israel Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 55. GCC Countries Next Generation Antibody Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million) Figure 56. Roche Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 57. Amgen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 58. Pfizer Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 59. Takeda Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 60. Daiichi Sankyo Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 61. Seagen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 62. Astellas Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 63. Immunomedics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 64. GSK Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 65. Immunocore Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 66. ADC Therapeutics Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2019-2024) Figure 67. Bottom-up and Top-down Approaches for This Report Figure 68. Data Triangulation Figure 69. Key Executives Interviewed
01. サンプル提供
ご購入前にサンプル(英語、日本語)が提供可能。
02. カスタマイズサービス
レポートの一部をご購入可能;基本バージョンに加え、ご要望に応じたカスタム委託調査も提供可能。
03. プロフェッショナルな日本語翻訳
AI翻訳ではなく、プロフェッショナルな日本語翻訳をご提供。納期:英語は2-4営業日以内、日本語は8-10営業日以内。
04. 多言語コミュニケーション
日本語、英語、中国語、ヒンディー語、ドイツ語、韓国語、フランス語の7ヶ国語でコミュニケーションサービスをご提供。
05. お支払方法
銀行振込(納品後、ご請求書送付)。
06. アフターサービス
ご購入後、ご質問があれば、3ヵ月以内に無料でアナリストと直接的に連絡できる。
請求書払いの場合:
レポート選択
見積もり依頼
メールでのご注文
入手(英語版は2〜4営業日、日本語版は8〜10営業日)
決済(後払い)
クレジットカード決済の場合:
レポート選択
ウェブサイトでのご注文
決済
入手(英語版は2〜4営業日、日本語版は8〜10営業日)